• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetics and plasma protein binding of two platinum cytostatics CHIP and CBDCA in rats.

作者信息

Láznícková A, Láznícek M, Kvĕtina J, Drobník J

出版信息

Cancer Chemother Pharmacol. 1986;17(2):133-6. doi: 10.1007/BF00306741.

DOI:10.1007/BF00306741
PMID:3521926
Abstract

Plasma protein binding and pharmacokinetic parameters of CHIP (cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV) and CBDCA (cis-diammine-1,1-cyclobutane dicarboxylate platinum II) were investigated in male Wistar rats. The plasma clearance of total and non-protein-bound platinum was determined and compared with that of 99mTc-DTPA. For binding experiments, a novel, simple, and quick method based on adsorption of non-protein-bound platinum species to charcoal was used. The clearance of total platinum after CHIP and CBDCA administration was markedly lower than the glomerular filtration rate (determined as the clearance of 99mTc-DTPA). The renal clearance of non-protein-bound platinum corresponded to 168% and 50% of the glomerular filtration rate for CHIP and CBDCA, respectively. These studies suggested that CHIP was excreted by the rat kidney.

摘要

相似文献

1
Pharmacokinetics and plasma protein binding of two platinum cytostatics CHIP and CBDCA in rats.
Cancer Chemother Pharmacol. 1986;17(2):133-6. doi: 10.1007/BF00306741.
2
Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.顺式-二氨-1,1-环丁烷二羧酸铂(II)在肾功能正常和受损患者中的药代动力学。
Cancer Res. 1984 Apr;44(4):1693-7.
3
The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.
Biochem Pharmacol. 1987 Jun 15;36(12):1925-32. doi: 10.1016/0006-2952(87)90490-4.
4
Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients.放射性标记的顺-二氨-1,1-环丁烷二羧酸铂(II)(CBDCA)在癌症患者体内的血液清除率。
Cancer Chemother Pharmacol. 1983;11(1):5-7. doi: 10.1007/BF00257407.
5
Comparative pharmacokinetics of four platinum cytostatics in rats.
Neoplasma. 1987;34(2):173-81.
6
In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma camera.
Cancer Chemother Pharmacol. 1985;14(3):253-7. doi: 10.1007/BF00258128.
7
Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles.铂类抗肿瘤药物与生物及非生物含硫亲核试剂反应的表征
Biochem Pharmacol. 1987 Jun 15;36(12):1955-64. doi: 10.1016/0006-2952(87)90494-1.
8
Effect of oxoplatinum and CBDCA on renal functions in rats.奥沙铂和卡铂对大鼠肾功能的影响。
Neoplasma. 1989;36(2):161-9.
9
Studies on the pharmacokinetics and metabolism of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) in the dog.
Cancer Treat Rep. 1982 Mar;66(3):509-16.
10
Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP), carboplatin (CBDCA), and iproplatin (CHIP).
Cancer Chemother Pharmacol. 1988;21(1):40-4. doi: 10.1007/BF00262736.

引用本文的文献

1
Shape changes induced by N-terminal platination of ubiquitin by cisplatin.顺铂诱导的泛素 N-末端铂化引起的构象变化。
J Am Soc Mass Spectrom. 2010 Jul;21(7):1097-106. doi: 10.1016/j.jasms.2010.02.012. Epub 2010 Feb 11.
2
Effects of storage on the binding of carboplatin to plasma proteins.
Cancer Chemother Pharmacol. 1995;35(3):254-6. doi: 10.1007/BF00686557.
3
In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin.
Cancer Chemother Pharmacol. 1987;20(4):271-6. doi: 10.1007/BF00262576.

本文引用的文献

1
Renal toxicity studies of protein-bound platinum(cis).
Chem Biol Interact. 1981 Jun;35(3):341-8. doi: 10.1016/0009-2797(81)90009-0.
2
Renal handling of cis-diamminedichloroplatinum(II).顺二氯二氨合铂(II)的肾脏处理
Cancer Treat Rep. 1980;64(12):1223-6.
3
Preparation and metabolism of a cisplatin/serum protein complex.顺铂/血清蛋白复合物的制备与代谢
Chem Biol Interact. 1980 May;30(2):223-35. doi: 10.1016/0009-2797(80)90128-3.
4
Treatment of intoxication with charcoal hemadsorption.
Drug Metab Rev. 1982;13(4):681-93. doi: 10.3109/03602538209011092.
5
Studies on the pharmacokinetics and metabolism of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) in the dog.
Cancer Treat Rep. 1982 Mar;66(3):509-16.
6
Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease.
Cancer Chemother Pharmacol. 1982;9(1):13-6. doi: 10.1007/BF00296754.
7
Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (CHIP) in patients with advanced cancer.顺二氯反二羟基双异丙胺铂(IV)(CHIP)在晚期癌症患者中的药代动力学
Cancer Chemother Pharmacol. 1983;11(1):23-8. doi: 10.1007/BF00257411.
8
Mechanisms of renal excretion of cisdichlorodiamine platinum.顺二氯二氨铂的肾脏排泄机制。
Res Commun Chem Pathol Pharmacol. 1983 Aug;41(2):255-64.
9
Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid.丙磺舒对人肾脏顺二氯二氨铂分泌的抑制作用。
Cancer Res. 1984 Aug;44(8):3632-5.
10
Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.顺式-二氨-1,1-环丁烷二羧酸铂(II)在肾功能正常和受损患者中的药代动力学。
Cancer Res. 1984 Apr;44(4):1693-7.